Get the Stockscreener App
2.43
6.58%
0.15
Pre-market:
2.49
0.06
+2.47%
Century Therapeutics Inc stock is traded at $2.43, with a volume of 1.38M.
It is up +6.58% in the last 24 hours and up +35.75% over the past month.
Century Therapeutics Inc is a biotechnology company that specializes in leveraging adult stem cells to develop cell therapy products aimed at treating cancer, autoimmune disorders, and inflammatory diseases. Their features a genetically engineered allogeneic cell therapy platform that incorporates induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and manufacturing capabilities. This comprehensive platform seeks to address the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and reducing development and supply risks.
See More
Previous Close:
$2.28
Open:
$2.33
24h Volume:
1.38M
Relative Volume:
0.82
Market Cap:
$212.39M
Revenue:
$2.24M
Net Income/Loss:
$-136.67M
P/E Ratio:
-1.0611
EPS:
-2.29
Net Cash Flow:
$-102.08M
1W Performance:
+11.47%
1M Performance:
+35.75%
6M Performance:
+407.52%
1Y Performance:
+301.59%
1-Day Range:
$2.25
$2.47
1-Week Range:
$2.105
$2.47
52-Week Range:
$0.3418
$2.71
Century Therapeutics Inc Stock (IPSC) Company Profile
Name
Century Therapeutics Inc
Sector
Industry
Phone
215-981-4000
Address
25 N 38TH STREET, 11TH FLOOR, PHILADELPHIA
Compare IPSC vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IPSC
Century Therapeutics Inc
|
2.43 | 199.28M | 2.24M | -136.67M | -102.08M | -2.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Century Therapeutics Inc Stock (IPSC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-08-24 | Initiated | Rodman & Renshaw | Buy |
| Aug-28-23 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-27-22 | Initiated | Chardan Capital Markets | Buy |
| Oct-31-22 | Initiated | Guggenheim | Buy |
| Oct-10-22 | Initiated | Canaccord Genuity | Buy |
| May-23-22 | Initiated | H.C. Wainwright | Buy |
| May-12-22 | Initiated | William Blair | Mkt Perform |
| Jul-13-21 | Initiated | BofA Securities | Buy |
| Jul-13-21 | Initiated | JP Morgan | Overweight |
| Jul-13-21 | Initiated | Piper Sandler | Overweight |
View All
Century Therapeutics Inc Stock (IPSC) Latest News
IPSC Financials: Income Statement, Balance Sheet & Cash Flow | Century Therapeutics, Inc. - Stock Titan
Should I buy Century Therapeutics Inc stock nowJuly 2025 Final Week & Weekly Watchlist for Consistent Profits - baoquankhu1.vn
Century Therapeutics, Inc. (NASDAQ:IPSC) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Century Therapeutics, Inc. (NASDAQ:IPSC) Short Interest Up 39.8% in February - MarketBeat
IPSC SEC FilingsCentury Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Aug Closing: How does Century Therapeutics Inc perform in inflationary periodsDollar Strength & Entry Point Confirmation Signals - baoquankhu1.vn
Century Therapeutics Inc expected to post a loss of 28 cents a shareEarnings Preview - TradingView
Century Therapeutics (NASDAQ:IPSC) Coverage Initiated by Analysts at TD Cowen - Defense World
Analysts Offer Insights on Healthcare Companies: Jazz Pharmaceuticals (JAZZ) and Century Therapeutics (IPSC) - The Globe and Mail
Movement Recap: Is Century Therapeutics Inc forming a bullish divergenceQuarterly Portfolio Report & Free Fast Gain Swing Trade Alerts - baoquankhu1.vn
Century Therapeutics to Participate in Upcoming Investor Conferences in March - Investing News Network
Century Therapeutics (NASDAQ:IPSC) Now Covered by Analysts at TD Cowen - MarketBeat
Stem cell therapy biotech Century Therapeutics heads to March investor events - Stock Titan
TD Cowen Initiates Century Therapeutics at Buy - marketscreener.com
TD Cowen initiates Century Therapeutics stock rating at Buy - Investing.com Australia
Financial Review: Century Therapeutics (NASDAQ:IPSC) and Hikma Pharmaceuticals (OTCMKTS:HKMPF) - Defense World
IPSCCentury Therapeutics, Inc. Latest Stock News & Market Updates - Stock Titan
What are the future prospects of Century Therapeutics Inc.2025 Support & Resistance & Fast Entry High Yield Stock Tips - mfd.ru
Point72 discloses 6.8% Century Therapeutics (IPSC) stake in 13G/A - Stock Titan
IPSC-derived NK Cells Clinical Trial Pipeline Gains Momentum: 12+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - GlobeNewswire Inc.
Is Century Therapeutics Inc. stock a dividend growth opportunityJuly 2025 Big Picture & Short-Term High Return Strategies - mfd.ru
Day Trade: Will Century Therapeutics Inc benefit from seasonality2025 Volume Leaders & High Accuracy Investment Signals - baoquankhu1.vn
Is Century Therapeutics Inc. forming a bullish divergence2025 Performance Recap & Low Volatility Stock Suggestions - mfd.ru
Clear Street reiterates Buy rating on Century Therapeutics stock at $6.60 - Investing.com Canada
Will Century Therapeutics Inc. stock benefit from automationGDP Growth & AI Enhanced Trade Execution Alerts - mfd.ru
Short Interest in Century Therapeutics, Inc. (NASDAQ:IPSC) Expands By 320.2% - MarketBeat
Bull Run: Will Century Therapeutics Inc stock go up in YEARShort Setup & Target Return Focused Stock Picks - baoquankhu1.vn
Is Century Therapeutics Inc. stock attractive for ETFs2025 Support & Resistance & Community Verified Trade Signals - mfd.ru
Century Therapeutics: A Very Promising Contender In The Type I Diabetes Mellitus Functional Cure Race - Seeking Alpha
Century Therapeutics, Inc. (NASDAQ:IPSC) Receives $3.80 Average PT from Brokerages - Defense World
Century Therapeutics, Inc. (NASDAQ:IPSC) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Century Therapeutics (IPSC) Price Target Increased by 10.75% to 4.20 - Nasdaq
Valuation Update: Is Oramed Pharmaceuticals Inc stock overvalued or fairly pricedMarket Growth Review & Real-Time Volume Analysis Alerts - baoquankhu1.vn
Chart Watch: Is Century Therapeutics Inc stock undervalued right nowSell Signal & Technical Confirmation Alerts - baoquankhu1.vn
Century Therapeutics (NASDAQ:IPSC) Lowered to "Sell" Rating by Wall Street Zen - MarketBeat
Century Therapeutics (NASDAQ:IPSC) Lowered to “Sell” Rating by Wall Street Zen - Defense World
Piper Sandler Highlights Century Therapeutics (IPSC) Cash Runway Through 2029, Upcoming IND Submission - Finviz
Risk Analysis: Will Century Therapeutics Inc benefit from current market trendsDollar Strength & Smart Money Movement Tracker - baoquankhu1.vn
Piper Sandler highlights Century Therapeutics (IPSC) cash runway through 2029, upcoming IND submission - MSN
7 Best Fast Growing Penny Stocks to Buy According to Analysts - Insider Monkey
Short Interest in Century Therapeutics, Inc. (NASDAQ:IPSC) Grows By 148.0% - MarketBeat
Why retail investors favor Century Therapeutics Inc. stockWeekly Trading Summary & High Accuracy Swing Entry Alerts - mfd.ru
Volume Report: Whats the RSI of Century Therapeutics Inc stock2025 Buyback Activity & Risk Managed Trade Strategies - baoquankhu1.vn
Are Biotech And Pharma Stocks Poised To Keep Climbing After Hitting 52-Week Highs? - Longbridge
Century Therapeutics (IPSC) upgraded to strong buy: Here's what you should know - MSN
Century Therapeutics (NASDAQ:IPSC) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Century Therapeutics Regains Nasdaq Compliance, Halts Reverse Split - TipRanks
How sensitive is Century Therapeutics Inc to inflationQuarterly Portfolio Summary & Safe Entry Momentum Stock Tips - baoquankhu1.vn
Century Therapeutics (IPSC) Upgraded to Strong Buy: Here's What You Should Know - Yahoo Finance
Deep Track Capital, LP's Strategic Acquisition of Century Therap - GuruFocus
Century Therapeutics stock price target raised to $4 from $2 at Piper Sandler - Investing.com India
Century Therapeutics Inc Stock (IPSC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.11%
6.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):